DAWN - Company ID 0001845337
The table below shows Day One Biopharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Revenue | $39.80M | $33.91M | $30.76M | $93.76M | $8.19M | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $31.42M | $36.15M | $39.62M | $33.56M | $92.11M | $40.21M |
Day One Biopharmaceuticals, Inc. reported annual revenue of $158.18M for fiscal year 2025. That is up 20.6% from $131.16M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $28.15M |
| $28.97M |
| $29.32M |
| $28.97M |
| $30.19M |
| $26.56M |
| Operating income | -$24.25M | -$34.97M | -$41.07M | $29.64M | -$114.81M | -$66.77M |
| Income tax | $0.00 | $0.00 | $0.00 | -$882.00K | $1.55M | $0.00 |
| Net income | -$19.73M | -$30.32M | -$36.00M | $37.04M | -$4.41M | -$62.41M |
| EPS (diluted) | -$0.19 | -$0.29 | -$0.35 | $0.38 | -$0.05 | -$0.72 |